LTGO insider transaction filings
Latigo Biotherapeutics, Inc. — 7 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-08-12. Screen LTGO transaction legs live →
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-08-12 | 4 | 5AM Ventures VI, L.P. — 10% owner 5AM Partners VI, LLC — 10% owner 5AM Opportunities II, L.P. — 10% owner 5AM Opportunities II (GP), LLC — 10% owner PARMAR KUSH — 10% owner Schwab Andrew J. — 10% owner | Conversion (C): 4,975,543 · Conversion (C): 2,350,419 · Conversion (C): 3,152,305 (derivative) @ $0 · Conversion (C): 1,823,238 (derivative) @ $0 · Conversion (C): 866,018 (derivative) @ $0 · Conversion (C): 1,484,401 (derivative) @ $0 | EDGAR |
| 2026-08-12 | 4 | Sanofi — 10% owner | Conversion (C): 494,800 · Conversion (C): 177,978 · Conversion (C): 494,800 (derivative) · Conversion (C): 177,978 (derivative) | EDGAR |
| 2026-08-11 | 4 | Westlake BioPartners Fund I, L.P. — 10% owner Westlake BioPartners GP I, LLC — 10% owner Westlake BioPartners Fund II, L.P. — 10% owner Westlake BioPartners GP II, LLC — 10% owner Westlake BioPartners Opportunity Fund I, L.P. — 10% owner Westlake BioPartners Opportunity GP I, LLC — 10% owner | Conversion (C): 938,979 · Conversion (C): 3,547,842 · Conversion (C): 1,027,635 · Conversion (C): 3,464,072 · Conversion (C): 1,484,401 · Conversion (C): 165,519 · +8 more | EDGAR |
| 2026-08-10 | 4 | Foresite Capital Management V, LLC — 10% owner Foresite Capital Fund V, L.P. — 10% owner Foresite Capital Opportunity Management V, LLC — 10% owner Foresite Capital Opportunity Fund V, L.P. — 10% owner Foresite Capital Management VI LLC — 10% owner Foresite Capital Fund VI LP — 10% owner | Conversion (C): 3,117,664 @ $0 · Conversion (C): 445,320 @ $0 · Conversion (C): 1,125,823 @ $0 · Conversion (C): 742,201 @ $0 · Purchase (P): 140,000 @ $18 · Conversion (C): 195,776 · +9 more | EDGAR |
| 2026-08-10 | 4 | SEIDENBERG BETH C — Director, 10% owner | Conversion (C): 938,979 · Conversion (C): 3,547,842 · Conversion (C): 1,027,635 · Conversion (C): 3,464,072 · Conversion (C): 1,484,401 · Conversion (C): 165,519 · +8 more | EDGAR |
| 2026-08-10 | 4 | Tananbaum James B. — Director, 10% owner | Conversion (C): 3,117,664 · Conversion (C): 445,320 · Conversion (C): 1,125,823 · Conversion (C): 742,201 · Purchase (P): 140,000 @ $18 · Conversion (C): 195,776 · +9 more | EDGAR |
| 2026-08-10 | 4 | SMITH TODD N — Director | Grant/award (A): 105,542 (derivative) @ $0 | EDGAR |
Recent 8-K events — Latigo Biotherapeutics, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-10 | 8-K | 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=LTGO returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →